Menu
Washingtoner
  • Home
  • Business
  • Technology
  • Construction
  • Arts
  • Real Estate
  • Health
  • Property
  • Software
Washingtoner

CCHR Urges FDA Overhaul to End Psychiatric Drug and Device Harms
Washingtoner/10275453

Trending...
  • Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
  • Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
  • Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
CCHR Urges FDA Overhaul
The Mental Health Watchdog calls for reforms to protect public safety, citing decades of antidepressant, electroshock, and psychedelic drug risks.

LOS ANGELES - Washingtoner -- The Citizens Commission on Human Rights International is calling for an overhaul of mental health agencies to eliminate potential conflicts of interest that may be putting patients at risk. The 55-year mental health industry watchdog said oversight should focus on the Food and Drug Administration (FDA), the agency tasked with ensuring the safety, efficacy, and security of drugs, biological products, and medical devices.

This reform is particularly urgent, CCHR says, given the FDA's ongoing failure to address critical issues, including the fact that it has yet to ban a skin electroshock device used as painful behavior modification on students with autism and intellectual and mental handicaps. In March 2024, the FDA announced that an electrical stimulation device (ESD) for behavior modification presents an "unreasonable and substantial risk of illness or injury." It called for submissions but has yet to issue a final order prohibiting it.[1] Meanwhile, children and adults continue to be subjected to it.

This is despite, as early as 2012, Juan Mendez, the United Nations Special Rapporteur on Torture said using this aversion therapy device constituted torture. According to a human rights lawyer, "The passage of electricity through anybody's body is clearly associated with pain and suffering."[2] Health agencies and psychiatric associations allow electroconvulsive therapy (ECT) to continue to be given to children and adolescents, as well as to any individual without their consent—a practice the UN also considers coercion and torture. No clinical trials have proven the safety and efficacy of ECT.[3]

CCHR has long advocated for the FDA to recognize the dangers of electroshock and to protect the public from the mass reliance upon antidepressants and other psychotropic drugs that pose significant health risks. The group says critical warnings about the link between antidepressants and increased suicidality and violent behavior have been ignored.

More on Washingtoner
  • $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
  • The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives

CCHR is concerned about how psychedelic drug applications are advancing through the agency, which, if approved, may increase acts of violence in the community. In June 2024, the FDA granted "Breakthrough Therapy Designation" to the hallucinogen psilocybin as an adjunct to treat "major depressive disorder." The designation is usually reserved for drugs that substantially improve over existing therapies in treating severe or life-threatening conditions.[4] Earlier, the FDA published guidelines for researchers to meet challenges in designing psychedelic drug development programs. "Psychedelic drugs may produce psychoactive effects such as mood and cognitive changes, as well as hallucinations. As a result, there is the potential for abuse of these drugs, which is a drug safety issue," according to the FDA.[5]

The U.S. is already plagued by acts of senseless violence, including school and community shootings, committed by people taking or withdrawing from psychiatric drugs. Psychedelics, if approved, could add to this. For years, the links between antidepressants and suicidality or violent behavior were suppressed, as documented by CCHR and medical experts.

The breakthrough SSRI antidepressant, fluoxetine, was approved in December 1987. By 1991, sales of the drug had reached nearly $1 billion and 3.5 million patients had taken it. The Los Angeles Times reported that antidepressants had been dogged by controversy over it being linked to suicide, homicide and other violence. The campaign exposing its risks was spearheaded by CCHR, a watchdog group that was established by the Church of Scientology in 1969 to investigate and expose psychiatric violations of human rights, including the failure to properly inform about treatment risks and harm. Sales "would be substantially higher" were it not for this campaign, said Steven Gerber, a securities analyst with Bateman Eichler in Los Angeles. According to the LA Times, "The campaign, which included involvement in dozens of criminal and civil suits, has nonetheless been surprisingly successful, alarming both potential patients and their doctors and contributing to the halt in growth of the drug's sales in [1991]."[6]

CCHR's Freedom of Information Act requests, review of court documents and media investigation findings reveal a scandalous history of cover-up of adverse drug effects. According to documents obtained in litigation, as early as 1984, German regulators had expressed concerns about fluoxetine and an increased risk of suicidality—three years before it was approved for the U.S. market. In 1990, FDA officer, Dr. David Graham reviewed the clinical trials and warned of large-scale under-reporting of suicidality.[7] An initially undisclosed memo from an antidepressant manufacturer admitted a rate of suicide to be 5.6 times higher than for the older tricyclic antidepressant, imipramine.[8] Adverse effects within two years of the drug being approved had reached nearly double those for an older antidepressant that had been on the market for 20 years.[9]

More on Washingtoner
  • The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
  • Digital Watchdog Launches New myDW Cloud Services
  • Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
  • Drone Light Shows Emerge as the New Standard in Live Event Entertainment
  • Lore Link is Here to Help Organize Your Game

FDA officials continued to find suicide and violence to be of concern, such as Dr. Andrew Mosholder, an FDA Safety Reviewer, who provided his findings to the FDA, but these were not released publicly.[10] The brazen refusal to publicly acknowledge the risks came to a head in 2004 when the U.S. House Energy and Commerce Subcommittee on Oversight and Investigations began an investigation.[11] Shortly after, the FDA added a black box warning of suicidality to SSRI antidepressant packaging for those 18 and younger, extending this later to age 24.

CCHR says that a comprehensive review of the FDA's review, approval and monitoring process for psychotropic drugs and psychiatric devices is vital to safeguarding public health and ensuring the protection of patients.

Sources:

[1] www.cchrint.org/2024/03/29/fda-again-pursues-ban-on-behavioral-electroshock-device/; www.thesunchronicle.com/news/local_news/fda-moves-again-to-ban-controversial-shock-therapy-devices-used-by-rotenberg-center/article_5b3792d4-3dd0-5745-a92b-332edf69b33f.html
[2] web.archive.org/web/20120623234442/http://www.myfoxboston.com/story/18840703/2012/06/20/un-investigating-judge-rotenberg-centers-use-of-shocks
[3] www.wisnerbaum.com/defective-medical-device-injuries/ect/
[4] med.uth.edu/psychiatry/2024/06/03/fda-grants-breakthrough-therapy-designation-to-cyb003-a-deuterated-psilocybin-analog-being-investigated-as-an-adjunctive-treatment-for-major-depressive-disorder-mdd/
[5] www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs
[6] www.latimes.com/archives/la-xpm-1992-01-08-fi-1610-story.html
[7] Joseph Glenmullen, M.D., Prozac Backlash, (New York, NY: Simon & Schuster, 2000) p. 162; www.wisnerbaum.com/our-successes/advocacy-campaigns/antidepressant-trials-adult-suicidality-data/
[8] Dr. Richard DeGrandpre, "Anti-depressants may be hazardous to your health," Hartford Advocate, 20 Aug 2002
[9] Craig McLaughlin, "The Perils of Prozac," San Francisco Bay Guardian, 16 May 1996
[10] www.cchrint.org/cchrs-exposure-of-antidepressant-risks-false-marketing-of-the-chemical-imbalance-theory/#_edn124
[11] "Barton, Greenwood Seek Info From FDA On Antidepressants," Rep. Barton's website, 24 Mar. 2004

Contact
Citizens Commission on Human Rights International
***@cchr.org


Source: Citizens Commission on Human Rights
Filed Under: Government

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • City of Spokane Announces 2026 Inclement Weather Plan
  • Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
  • Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
  • Spokane City Council Adopts Engagement and Enforcement Ordinances
  • Spokane City Council Approves Safe and Welcome in Spokane Ordinance
  • $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
  • $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
  • Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
  • Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
  • Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
  • Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
  • Spokane: Flags Lowered for Coeur d'Alene Fire Department and Kootenai County Fire and Rescue
  • AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
  • The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
  • Spokane: City Details Fourth of July Activities, Closures
  • $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
  • Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
  • Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
  • Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK
  • Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
_catLbl0 _catLbl1

Popular on Washingtoner

  • Experience Trembling Firsthand with the New AgeMan® Tremor Simulator - 194
  • Advanced Solar Space Technology; Record Efficiency of 15.7%; Agreement to Provide NOVI Space with Rollable PV Array Blankets for Space Launch in 2026 - 175
  • DealMagik Successfully Concludes National Floral Design Contest with Over 150 Submissions - 166
  • ASI Accelerates iMIS® Innovation by Acquiring CSI's Product Suite and Expert Team - 152
  • Keebos Launches New Universal Pearl Strap That Attaches to Any Phone Case - 143
  • Integris Composites Joins Paris Air Show at USA Pavilion - 123
  • A Cosmic Banter: William Shatner & Neil deGrasse Tyson Go Wild on The Late Show with Stephen Colbert - 120
  • Last Call - Submit Your Proposal for the 2025 OpenSSL Conference in Prague - 116
  • SheepFeast Launches "1 Million Discipled" Global Initiative to Empower Disciple-Making Around the World - 111
  • Patrick Aloni Joins Historic Gold and Copper Discovery in Argentina with Multimillion-Dollar Stake

Similar on Washingtoner

  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
  • The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
  • Digital Watchdog Launches New myDW Cloud Services
  • Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
  • Spokane: Underhill Sport Court Renovation Ribbon Cutting July 3, 10 a.m.
  • Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
  • Infinite Health Introduces Cutting-Edge Regenerative Medicine for Wound Care with Trip Goolsby, MD
  • Spokane: Water System Project Will Impact Northwest Intersection
Copyright © 2025 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute